| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Concise Reviews |
a Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland, USA;
b University of Ulm, Department of Internal Medicine III, Ulm, Germany;
c Laboratory of Cell Biology, National Cancer Institute, NIH, Bethesda, Maryland, USA
Key Words. Chemotherapy • Hematopoietic stem cells • Multidrug resistance • Myelosuppression • P-glycoprotein • Dihydrofolate reductase • Transgenic animals • Retroviral vectors
Correspondence:
Dr. M.M. Gottesman, Laboratory of Cell Biology, National Cancer Institute, NIH, Building 37, Room 1B22, 37 Convent Drive, MSC 4255, Bethesda, MD 20892-4255, USA.
Chemoresistance genes, initially considered to be a major impediment to the successful treatment of cancer, may become useful tools for gene therapy of cancer and of genetically determined disorders. Various target cells are rendered resistant to anticancer drugs by transfer of chemoresistance genes encoding P-glycoprotein, the multidrug resistance-associated protein-transporter, dihydrofolate reductase, glutathione-S-transferase, O6-alkylguanine DNA alkyltransferase, or aldehyde reductase. These genes can be used for selection in vivo because of the pharmacology and pharmacokinetics of their substrates. In contrast, several other selectable marker genes conferring resistance to substrates like neomycin or hygromycin can only be utilized in tissue culture. Possible applications for chemoresistance genes include protection of bone marrow and other organs from adverse effects caused by the toxicity of chemotherapy. Strategies have also been developed to introduce and overexpress nonselectable genes in target cells by cotransduction with chemoresistance genes. Thereby expression of both transgenes can be increased following selection with drugs. Moreover, treatment with chemotherapeutic agents should restore transgene expression when or if expression levels decrease after several weeks or months. This approach may improve the efficacy of somatic gene therapy of hematopoietic disorders which is hampered by low or unstable gene expression in progenitor cells. In this article we review preclinical studies in tissue culture and animal models, and ongoing clinical trials on transfer of chemoresistance genes to hematopoietic precursor cells of cancer patients.
This article has been cited by other articles:
|
|
 |
|
  T. Ueda, S. Brenner, H. L. Malech, S. M. Langemeijer, S. Perl, M. Kirby, O. A. Phang, A. E. Krouse, R. E. Donahue, E. M. Kang, et al. Cloning and Functional Analysis of the Rhesus Macaque ABCG2 Gene: FORCED EXPRESSION CONFERS AN SP PHENOTYPE AMONG HEMATOPOIETIC STEM CELL PROGENY IN VIVO J. Biol. Chem., January 14, 2005; 280(2): 991 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Hanazono, K. Terao, and K. Ozawa Gene Transfer into Nonhuman Primate Hematopoietic Stem Cells: Implications for Gene Therapy Stem Cells, January 1, 2001; 19(1): 12 - 23. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y. RAVIV, A. PURI, and R. BLUMENTHAL P-glycoprotein-overexpressing multidrug-resistant cells are resistant to infection by enveloped viruses that enter via the plasma membrane FASEB J, March 1, 2000; 14(3): 511 - 515. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. A. Moscow, H. Huang, C. Carter, K. Hines, J. Zujewski, G. Cusack, C. Chow, D. Venzon, B. Sorrentino, Y. Chiang, et al. Engraftment of MDR1 and NeoR Gene-Transduced Hematopoietic Cells After Breast Cancer Chemotherapy Blood, July 1, 1999; 94(1): 52 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Yelin, D. Rotem, and S. Schuldiner EmrE, a Small Escherichia coli Multidrug Transporter, Protects Saccharomyces cerevisiae from Toxins by Sequestration in the Vacuole J. Bacteriol., February 1, 1999; 181(3): 949 - 956. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
